South Dakota AG Says Rescheduling Has 'Negligible Impact' on Medical Program

The attorney general's position

South Dakota's attorney general said a federal move off Schedule I would change little for the state's medical marijuana program, according to Marijuana Moment's Oct. 13 report.

The headline conclusion is clear: 'negligible impact.' The underlying signal doesn't include the full text of the attorney general's analysis, so this story doesn't characterize reasoning beyond that conclusion.

That caveat matters. A one-line bottom line from a state's top lawyer is a position, not a ruling. It doesn't bind the Department of Health, licensees, or a court.

Why the state program stays largely intact

South Dakota's medical program operates under state statute, so a change in the federal schedule doesn't rewrite the licensing rules.

Voters created the program through Initiated Measure 26 in November 2020, with roughly 70% support. The South Dakota Department of Health administers patient cards and licenses cultivation, manufacturing, testing and dispensary facilities, and none of that machinery depends on marijuana sitting in Schedule I.

On a strict reading, the state's authority comes from its own code, not from the federal schedules. Moving marijuana to Schedule III doesn't repeal or amend those provisions. Nor does it turn the program into anything the federal government has approved.

Adult-use history reinforces the point. Voters approved a recreational measure in 2020, the state Supreme Court struck it down in 2021, and later ballot attempts failed. The medical program has been the stable piece.

Where 280E changes the math

The one concrete financial effect of rescheduling would be the end of 26 U.S.C. §280E for state-licensed operators.

Section 280E denies business deductions for any trade or business 'trafficking' in controlled substances 'within the meaning of schedule I and II.' On a strict reading, a Schedule III substance falls outside the text. Licensed South Dakota operators would then deduct ordinary expenses like rent, payroll and utilities under the standard IRC rules.

That's a federal effect, not a state one. South Dakota has no broad-based personal or corporate income tax, so there's no state-level 280E conformity question to resolve. The relief would show up on federal returns.

Benefit size would depend on each operator's cost structure. High-overhead dispensaries gain the most. Operators already near break-even gain less.

One timing question sits outside the attorney general's analysis: whether relief applies prospectively or reaches open tax years. That turns on the effective date of the final federal action and IRS guidance, and neither appears in this signal.

What rescheduling doesn't fix

A Schedule III designation leaves marijuana a federally controlled substance, so most compliance friction stays in place.

Here's what stays the same:

• Federal illegality of state-licensed sales. Schedule III substances still require DEA registration and fall under prescription rules that state dispensaries don't follow.
• Banking. Rescheduling doesn't amend the federal banking statutes, so account access remains a bank-by-bank risk decision.
• Interstate commerce. Transport across state lines stays prohibited.
• State licensing. Department of Health rules, fees and patient-card requirements continue unchanged.

That's why 'negligible' is defensible. The attorney general's read puts the program's legal foundation where it already sits, in state law.

The operator and patient read

For operators the story is tax, not licensure; for patients it's close to nothing.

Patients should see no change in card eligibility, product access or purchase rules. Operators should treat 280E relief as a modeling question, not a certainty, until the final federal action and IRS guidance are in hand. For full background on the federal track, see the CannIntel topic hub on DEA marijuana rescheduling.

The attorney general's framing is tidy. It isn't a prediction that the federal process will be smooth.

Multistate operators holding a South Dakota license face a different calculation. Their consolidated federal exposure depends on the entire footprint, not one state's program, which means Colorado and California licensees would feel the 280E change far more than South Dakota's small market.

What to watch next

The signals that matter are the final DEA action's effective date, IRS guidance on §280E, and any Department of Health notice to licensees.

Watch whether the Department of Health issues guidance to licensees, and whether the IRS addresses prior-year treatment. Either would show whether 'negligible' holds beyond the attorney general's headline.